Journal Pre-proof

Multiplex analysis of Human Polyomavirus diversity in kidney transplant recipients with BK virus replication

Yilin Wang, Robert Strassl, Ilkka Helanterä, Stephan W. Aberle, Gregor Bond, Klaus Hedman, Lukas Weseslindtner

PII: S1386-6532(19)30195-7
DOI: <https://doi.org/10.1016/j.jcv.2019.08.012>
Reference: JCV 4187

To appear in: *Journal of Clinical Virology*

Received Date: 25 June 2019
Accepted Date: 26 August 2019

Please cite this article as: Wang Y, Strassl R, Helanterä I, Aberle SW, Bond G, Hedman K, Weseslindtner L, Multiplex analysis of Human Polyomavirus diversity in kidney transplant recipients with BK virus replication, *Journal of Clinical Virology* (2019), doi: <https://doi.org/10.1016/j.jcv.2019.08.012>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier.

Multiplex analysis of Human Polyomavirus diversity in kidney transplant recipients with BK virus replication

Running Title:

Polyomavirus diversity after kidney transplantation

Yilin Wang ¹, Robert Strassl MD ², Ilkka Helanterä MD, PhD ³, Stephan W. Aberle MD ⁴, Gregor Bond MD, PhD ², Klaus Hedman MD, PhD ^{1,4} and Lukas Weseslindtner MD ^{1,4}

¹ Department of Virology, University of Helsinki, Finland

² Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria

³ University of Helsinki and Helsinki University Hospital, Transplantation and Liver Surgery, Finland

⁴ Center for Virology, Medical University of Vienna, Austria

⁵ Helsinki University Hospital, HUSLAB, Helsinki, Finland

Corresponding author:

Lukas Weseslindtner, Center for Virology, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria, Tel.: 004314016065509, Fax: 0043 140160965599, e-mail: lukas.weseslindtner@meduniwien.ac.at

Highlights

- In this study performed a comprehensive longitudinal genoprevalence analysis of 13 diverse Human polyomaviruses (HPyVs) using a novel multiplex assay in kidney transplant recipients (KTRs) with high level BK (BKPyV) and JC virus DNAemia and Polyomavirus associated nephropathy.
- In total, we included 400 serum and 388 urine samples obtained pairwise from 99 KTRs during the post-transplant follow-up.

- Three different recently discovered non-BKPyV/JCPyV HPyVs, Human Polyomavirus 9, Merkel cell Polyomavirus (MCPyV) and Trichodysplasia spinulosa associated Polyomavirus, were detected in 11 blood and 21 urine samples from 21 patients.
- DNAemia of these viruses occurred frequently during high level BKPyV DNAemia and PVAN. However, no statistically significant increase of the detection frequency was observed due to progression of BKPyV replication for blood samples.
- Of note, the detection rate of MCPyV in urine was significantly higher during BKPyV DNAemia in KTRs with histologically verified PVAN

Abstract: Background:

While the pathogenicity of the two initially identified Human Polyomaviruses (HPyVs), BK Virus (BKPyV) and JC Virus (JCPyV) has been intensely studied, there is only limited data, on whether the occurrences of the recently discovered HPyVs correlates with high level BKPyV replication and progression towards Polyomavirus associated nephropathy (PVAN).

Methods:

Therefore, we performed a comprehensive longitudinal genoprevalence analysis of 13 HPyVs using a novel multiplex assay including 400 serum and 388 urine samples obtained from 99 kidney transplant recipients (KTRs), grouped by quantitative BKPyV DNA loads and evidence of manifest BKPyV associated disease (histologically verified PVAN, high urinary decoy cell levels and concurrent decrease of renal function).

Results:

In total, 3 different non-BKPyV/JCPyV HPyVs, Human Polyomavirus 9, Merkel Cell Polyomavirus (MCPyV) and Trichodysplasia Spinulosa associated Polyomavirus were detected in 11 blood and 21 urine samples from 21 patients. Although DNAemia of these viruses occurred more frequently during high level BKPyV DNAemia and PVAN, the increase of the detection frequency due to progression of BKPyV replication did not reach statistical significance for blood samples. The positive detection rate of MCPyV in urine, however, was significantly higher during BKPyV DNAemia in 19 KTRs of our cohort who suffered from histologically verified PVAN ($p=0.005$). In one individual with PVAN, continuous long-term shedding of MCPyV in urine was observed.

Conclusion:

In our cohort the recently discovered HPyVs HPyV9, TSPyV and MCPyV emerged in blood from KTRs with variable kinetics, while detection of MCPyV DNAemia occurred more frequently during BKPyV DNAemia in patients with PVAN.

Key words:

Human polyomavirus, diversity, HPyV, kidney transplantation recipients, kidney, renal, transplant, multiplex

List of Abbreviations:

BKPyV, BK Polyomavirus, DNA, deoxyribonucleic acid, D, donor, GFR, glomerular filtration rate, HPyV, Human Polyomavirus, HPyV9, Human Polyomavirus 9, KTRs, kidney transplant recipients, JCPyV, JC Polyomavirus, KTRs, kidney transplant recipients, LOD, Limit of detection, MCPyV, Merkel Cell Polyomavirus, ml, milliliter, PCR, polymerase chain reaction, PVAN, Polyomavirus associated nephropathy, qPCR, quantitative PCR, R, recipient, TSVPyV, Trichodysplasia spinulosa polyomavirus

Introduction

BK Virus (BKPyV) and JC virus (JCPyV) were isolated as first Human Polyomaviruses (HPyVs) from urine of a nephropathic kidney transplant recipient (KTR) and from brain tissue of a patient with progressive multifocal leukoencephalopathy and named by the initials of the respective patients (1, 2).

To date, the following additional HPyVs are known to exist: Karolinska Institute and Washington University Polyomaviruses, Merkel cell Polyomavirus (MCPyV), Trichodysplasia spinulosa associated Polyomavirus (TSPyV), Human Polyomaviruses 6, 7, 9, 12, Malawi Polyomavirus, Saint Louis Polyomavirus, New Jersey Polyomavirus and Lyon IARC polyomavirus, which has not yet been assigned to a polyomavirus species (3-7).

Prolonged and asymptomatic shedding of these viruses occurs in healthy individuals, and in immunocompromised individuals they may cause severe disease (3, 8). MCPyV was associated with development of Merkel cell carcinoma (9), while TSPyV can cause a rare follicular skin disease (10). For the recently discovered HPyVs no definitive association with any major clinical manifestation has been verified.

BKPyV and JCPyV, in contrast, have been functionally linked with clinical manifestations in KTRs (11-13). Indeed, Polyomavirus associated nephropathy (PVAN) is a severe disease, that may affect up to 10% of all KTRs and cause allograft loss in 10% to 100% of affected patients (11-15). While BKPyV is the primary causative agent of PVAN, JCPyV can also trigger PVAN in rare cases (12, 15, 16).

Thus, the question opens up whether the newly discovered HPyVs occur more frequently in KTRs with BKPyV-induced PVAN. So we performed a comprehensive genoprevalence analysis of 13 HPyVs in blood and urine samples collected pairwise from KTRs with BKPyV DNAemia with and without evidence for progression towards PVAN.

Materials and Methods

Patients and samples

This retrospective study included 400 plasma and 388 urine samples from 99 KTRs (35 female, 64 male; mean age: 57 years, range: 19-79), who received a kidney transplant between March 2008 and September 2014. Detailed clinical information is given in Supplemental Material and Methods and Supplemental Table 1. From each patient, plasma and urine samples were collected pairwise at the same day respectively due to virological routine post-transplant surveillance (386 sample pairs, 14 plasma and 2 urine samples were acquired without corresponding samples). The

median number of samples per patient was 3 (plasma and urine) respectively. The median interval between sample acquisition post-transplant was 79 days for plasma and 84 days for urine (range: 11-561). Samples were acquired during the following periods post-transplant (plasma/urine): 0 (at transplantation): n= 5/4, post-transplant day 1-90: n=66/62, 91-180: n=107/102, 181-270: n=72/72, 271-360: n=46/47, 361-450: n=24/22, 451-540: n=19/19, 541-630: n=13/13, 631-720: n=15/15, >720: n=33/32.

The study protocol was approved by the ethics committee of the Medical University of Vienna (EK2064/2016). Since the samples had been acquired for virological diagnosis in the past, the ethics committee concluded that no written informed consent from patients was required (EK1035/2016).

Quantitative BKPyV and JCPyV PCR

In each urine and plasma sample BKPyV and JCPyV DNA was quantified due to routine surveillance post-transplant using a testing schedule and protocol included in Supplementary Material and Methods.

DNA isolation for HPyV multiplex assay

For HPyV multiplex assays DNA was isolated from EDTA-plasma by QIAmp Blood-Mini kit, and from urine by QIAamp Viral RNA kit (both Qiagen, Germany), according to the manufacturer's instructions. Isolated DNA from 200µL EDTA-plasma was finally eluted into 100 µL AE buffer and DNA from 140µL urine was eluted into 60µL of AVE buffer (both Qiagen, Germany).

HPyV multiplex PCR

Viral DNA of each sample was measured using a novel bead-based multiplex PCR for 13 HPyVs, as described previously (17, 18). More detailed information is given in Supplementary Material and Methods.

Bead-based suspension assay

To semi-quantify all 13 HPyVs simultaneously, we applied bead-based suspension assay (Luminex) as described previously (17). Detailed information on the protocol, the confirmation method and assessment of sensitivity and specificity is given in Supplemental Material and Methods (10, 19, 20).

Statistical methods

Agreement between BKPyV/JCPyV qPCR and multiplex PCR was analyzed using a two-way contingency table and Altman scheme (almost perfect: kappa 1.00, very good: kappa 0.81-0.99, good: kappa 0.61–0.80, fair: kappa 0.21–0.40 and poor: kappa <0.20). The association between the detection rate non-BKPyV/JCPyV HPyVs and evidence for PVAN progression was analyzed using Fisher's exact test. For all statistical tests, a two-sided *p*-value of <0.05 was considered statistically significant and GraphPad Prism version 5.0 software was used.

Results

Detection of BKPyV and JCPyV by qPCR

Out of 400 plasma and 388 urine samples, BKPyV DNA was detected by quantitative PCR (qPCR) in 260 plasma and 305 urine samples and JCPyV in 67 plasma and 170 urine samples. Eighty-three of the 99 KTRs (84%) particularly displayed one or more episodes of BKPyV DNAemia post-transplant (median BKPyV DNA load: 3.6×10^4 copies/ml, range: 1.0×10^2 - 1.5×10^9). Of these 83, 50 additionally

displayed JCPyV DNAemia at any time during follow-up (median viral load: 3.2×10^3 copies/ml, range: 1.0×10^2 - 8.0×10^5). Two patients (2%) displayed JCPyV DNAemia alone. Fourteen out of the 99 KTRs (14%) did not display BKPyV or JCPyV detection, neither in urine nor in blood. Patient baseline characteristics did not significantly differ among these groups (Supplemental Table 1).

Comparison of single and multiplex PCRs for BKPyV and JCPyV detection

All samples quantified for BKPyV and JCPyV DNA by qPCR were retested with multiplex PCR. The comparative results are shown in Table 1. To evaluate the performance of multiplex PCR Cohen's kappa values were calculated based on qPCRs positivity. Agreement between the two assays was good to very good (kappa for BKPyV in plasma=0.89, for BKPyV in urine=0.91, for JCPyV in plasma=0.76 and for JCPyV in urine=0.75). Discrepant test results mainly occurred at DNA loads $< 1 \times 10^3$ copies/mL.

Detection of non-BKPyV/JCPyV HPyVs

Newly discovered HPyVs (other than BKPyV and JCPyV) could be detected in a total of 21 of all 99 KTRs (21.2%). In total, 3 different non-BKPyV/JCPyV HPyVs were detected. As shown in Figure 1, Human Polyomavirus 9 (HPyV9) was detected in a blood sample from one patient and MCPyV was detected in 9 blood and 21 urine samples from a total 20 KTRs (Figure 2). In one of those 20 patients, TSPyV was detected in a subsequently acquired blood sample.

The detection rates of MCPyV, HPyV9 and TSPyV in plasma samples were 8.1% (8/99), 1.1% (1/99) and 1.1% (1/99) respectively. Viral DNA concentrations in plasma were low and were only found in patients who displayed BKPyV and/or JCPyV DNAemia during the follow-up.

MCPyV detection

MCPyV was detected in 9 blood samples from 8 KTRs, in 2 patients exactly at the day of transplantation, in the remaining individuals between the 32nd and the 239th day post-transplant (Figure 2). The median MCPyV DNA load was 5.9×10^2 copies/mL (range: 1.2×10^2 - 1.4×10^3 copies/mL). MCPyV detection in plasma coincided with BKPyV DNAemia in 6 KTRs and with PVAN in one patient respectively. In one of these individuals MCPyV was detectable in blood 2 months prior to BKPyV DNAemia (patient #73, Figure 2).

In urine, MCPyV DNA was detected in 16 KTRs (16.2%) with a median viral load of 6.3×10^2 copies /mL (range: 1.2×10^2 - 4.2×10^4 copies/mL). In contrast, to MCPyV detection in blood, MCPyV DNAuria occurred during the entire post-transplant follow-up, ranging from the transplantation day to the 796th day post-transplant. Out of the 21 episodes of MCPyV DNAuria, 9 occurred simultaneously with BKPyV DNAemia and 5 emerged when PVAN was diagnosed (Figure 2).

In 6 cases MCPyV was detected in multiple blood and/or urine samples from the same patient respectively. As shown in Figure 2, one of these patients (patient #74) displayed persistent MCPyV DNA shedding in urine (with 4 positive samples over a period of 686 days) which started when PVAN developed and continued during subsequent and prolonged high-level BKPyV DNAemia.

HPyV 9 and TSPyV detection

HPyV9 DNA (3.4×10^3 copies/mL) was detected in a blood sample from a 27-year-old male at the same time point when BKPyV DNA loads in urine and in blood peaked and PVAN was verified histologically (126th day post-transplant). In two

consecutive samples (obtained after 2 and 12 months), as well as in all corresponding urine samples, HPyV 9 was undetectable.

Furthermore, TSPyV DNA was found in one blood sample from a 59-year-old male (patient #78, Figure 2) at the 32nd month post-transplant, who did not display BKPyV DNAemia at the same time, but had experienced a combined episode of MCPyV DNAuria and BKPyV DNAemia 111 days earlier. The TSPyV DNA load, however, was too low to be quantified.

Detection rate of non-BKPyV/JCPyV HPyVs in relation to severity of BKPyV DNAemia

Finally, we analyzed whether HPyV detection (other than BKPyV and JCPyV) differed among patients with BKPyV DNAemia in relation to the clinical severity of this DNAemia. Therefore, we grouped the 83 BKPyV DNAemic KTRs based on quantitative BKPyV DNA loads and PVAN evidence (Table 2). Nine-teen KTRs of our cohort only displayed peak DNA loads lower than 10^4 copies/ml during any BKPyV DNAemia episode. Decoy cell levels and incidence rates of a concurrent decrease of renal function were significantly lower in these KTRs than in patients with BKPyV DNA levels $>10^4$ copies/ml. BKPyV DNA loads exceeded 10^4 copies/ml in 45 KTRs, in whom significantly higher decoy cell levels and higher incidence rates of decreased renal function occurred, but no biopsy was performed during BKPyV DNAemia (Table 2). In 19 KTRs, presence of PVAN was additionally confirmed in a biopsy (also see Supplemental Material and Methods), and these individuals displayed the highest BKPyV DNA loads, decoy cell levels and highest rates of a concurrent decrease of renal function (Table 2).

As shown in Table 2, the detection rate of MCPyV in urine, but not in blood, was significantly higher during BKPyV DNAemia episodes in these 19 KTRs with

verified PVAN than in the other patients with BKPyV DNAemia ($p=0.005$). For the detection of non-BKPyV/JCPyV HPyVs in blood, there was no statistical evidence for such an association between progression of BKPyV replication and increased detection rates, and this applied to detection during or in absence of BKPyV DNAemia (Table 2). Of note, additional JCPyV DNAemia occurred more frequently in KTRs with high level BKPyV DNAemia (Table 2).

Discussion

In order to identify whether the newly discovered HPyVs occur more frequently in KTRs with clinically progressed BKPyV replication we performed a retrospective, comprehensive genoprevalence analysis of 13 HPyVs in a cohort of KTRs with and without high level BKPyV DNAemia, grouped by viral loads and histological evidence of PVAN. Although HPyV9 and MCPyV DNAemia frequently occurred during BKPyV DNAemia episodes and PVAN, we found no statistical evidence for an increased occurrence of the newly identified HPyVs in blood due to clinically manifest BKPyV replication. A higher detection rate of MCPyV DNAemia however, was observed in our cohort when patients developed PVAN.

Indeed, to our knowledge, only one publication has described all 13 first-detected HPyVs in longitudinal kidney transplantation cohort (21). In this previous study low detection frequencies of non-BKPyV/JCPyV HPyVs were reported. Recently, an analysis on the impact of HPyV9 and TSPyV coinfection on BKPyV DNAemia demonstrated a positive association between HPyV9 seropositivity and subsequent PVAN development, while TSPyV DNAemia was only detected in a small number of KTRs (22).

With the aim of extending these existing findings, we focused on investigating HPyVs in a specifically selected KTR cohort with high-level BKPyV DNAemia and

PVAN and analyzed pairs of blood and urine samples. In agreement with previous data, we detected two newly discovered HPyVs, HPyV 9 and TSPyV in blood samples, respectively, confirming generally low detection frequencies of these viruses (20, 21). We detected MCPyV at higher frequencies in blood, but even more in urine samples.

Of note, in our study cohort the detection rates of MCPyV in urine, but not in blood, were higher in patients with histologically verified PVAN than in patients with mere high level BKPyV DNAemia, and persistent MCPyV shedding with multiple positive urine samples was specifically observed in an individual with PVAN. Similar to our findings, previous studies reported that MCPyV viruria and occasionally prolonged shedding were detected in adult and pediatric KTRs (21, 23). Furthermore, Hussein et al. found MCPyV viruria in 30% of recipients, and that low-level shedding of MCPyV in urine occurred in immunosuppressed and immunocompetent subjects (24). Together with our data this indicates that MCPyV might persist in renal tubule or bladder epithelial cells and could reactivate similarly to BKPyV, although the primary latency site is not entirely elucidated (21).

Another accordance with previous studies was that we detected non-BKPyV/-JCPyV HPyVs in blood at low DNA levels, with most of the viral DNAemia episodes occurring at a single time point mostly during the first 4 months post-transplant (21, 23-26). This observation indicates that the early phase of high dose immunosuppression after transplantation could not only trigger BKPyV but also MCPyV reactivation (13, 15, 21).

Indeed, we here initially applied a new multiplex method in a large cohort of KTRs, able to simultaneously assess 13 HPyVs with a single assay. Since qPCR was used for clinical routine surveillance of BKPyV and JCPyV replication, we were able to determine the inter-assay variability and found good agreement between the

multiplex assay and qPCR, which further validates the newly developed method. The detection limits for BKPyV and JCPyV were lower using qPCR, proposing that the multiplex assay is more suitable for screening studies for the full spectrum of HPyVs rather than clinical follow-up of BKPyV and JCPyV.

Another interesting aspect of the current data, was that HPyV9 DNAemia occurred in one sample with a high BKPyV DNA load, obtained from a patient during an episode of histologically verified PVAN. A previous study first described the presence of HPyV9 in blood samples from KTRs; however, the prevalence in our study, was significantly lower than the original report (20). As noted, our multiplex assay displayed a lower sensitivity for BKPyV than qPCR; and divergent detection rates could be due to differences in primer sets and sample materials (21, 25). Notably, HPyV9 DNA was absent from the patient's corresponding urine sample, as well as from all urine samples from the KTRs, suggesting that HPyV9 may not be excreted through the urinary tract at detectable levels.

In summary, we systematically and comprehensively studied the genoprevalence of 13 HPyVs with a new assay in a cohort of KTRs with high-level BKPyV DNAemia and demonstrated that DNAemia of MCPyV and to a lesser extent of HPyV9 and TSPyV emerged with variable kinetics during post-transplant follow-up. MCPyV DNAemia, however, was detected in our cohort with a higher frequency in patients who in addition to BKPyV DNAemia also displayed histological evidence of PVAN.

Acknowledgements

Funding:

The study was funded by the Jane and Aatos Erkko Foundation, the Helsinki University Hospital Research & Education Fund, the Medical Society of Finland (FLS), and the Sigrid Jusélius Foundation, and the Finnish Society of Sciences and Letters.

The research stay of Lukas Weseslindtner at the Department of Virology Department of Virology of the University of Helsinki was funded by the Austrian Science fund (Erwin Schrödinger fellowship J3962-B30).

Competing interests:

None declared

Ethical approval:

The study protocol was approved by the ethics committee of the Medical University of Vienna (EK2064/2016). Since the samples had been acquired for virological diagnosis in the past, the ethics committee concluded that no written informed consent from patients was required (EK1035/2016).

Authorship Statement:

Yilin Wang contributed new analytic tools and participated in performance of the research, writing of the paper and data analysis, Robert Strassl and Ilkka Helanterä participated in conceptualization of research design, Gregor Bond participated in research design and writing of the paper, Stephan Aberle contributed analytic tools. Klaus Hedman contributed new analytic tools and participated in research design and writing of the paper, Lukas Weseslindtner participated in research design, performance of the research, data analysis and writing of the paper.

References

1. Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. *Lancet* 1971; 1 (7712): 1253.
2. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. *Lancet* 1971; 1 (7712): 1257.
3. Moens U, Krumbholz A, Ehlers B, et al. Biology, evolution, and medical importance of polyomaviruses: An update. *Infect Genet Evol* 2017; 54: 18.
4. Gheit T, Dutta S, Oliver J, et al. Isolation and characterization of a novel putative human polyomavirus. *Virology* 2017; 506: 45.
5. Feltkamp MC, Kazem S, van der Meijden E, Lauber C, Gorbalenya AE. From Stockholm to Malawi: recent developments in studying human polyomaviruses. *J Gen Virol* 2013; 94 (Pt 3): 482.
6. Lim ES, Reyes A, Antonio M, et al. Discovery of STL polyomavirus, a polyomavirus of ancestral recombinant origin that encodes a unique T antigen by alternative splicing. *Virology* 2013; 436 (2): 295.
7. Scuda N, Hofmann J, Calvignac-Spencer S, et al. A novel human polyomavirus closely related to the african green monkey-derived lymphotropic polyomavirus. *J Virol* 2011; 85 (9): 4586.
8. Dalianis T, Hirsch HH. Human polyomaviruses in disease and cancer. *Virology* 2013; 437 (2): 63.
9. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. *Science* 2008; 319 (5866): 1096.
10. van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. *PLoS Pathog* 2010; 6 (7): e1001024.
11. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. *New Engl J Med* 2002; 347 (7): 488.
12. Drachenberg CB, Hirsch HH, Papadimitriou JC, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. *Transplantation* 2007; 84 (3): 323.
13. Hirsch HH, Babel N, Comoli P, et al. European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. *Clin Microbiol Inf* 2014; 20 Suppl 7: 74.
14. Sawinski D, Goral S. BK virus infection: an update on diagnosis and treatment. *Nephrol Dial Transplant* 2015; 30 (2): 209.
15. Trofe-Clark J, Sawinski D. BK and Other Polyomaviruses in Kidney Transplantation. *Semin Nephrol* 2016; 36 (5): 372.
16. Delbue S, Ferraresso M, Ghio L, et al. A review on JC virus infection in kidney transplant recipients. *Clin Dev Immunol* 2013; 2013: 926391.
17. Sadeghi M, Wang Y, Ramqvist T, et al. Multiplex detection in tonsillar tissue of all known human polyomaviruses. *BMC infectious diseases* 2017; 17 (1): 409.
18. Wang Y, Keinonen A, Koskenmies S, et al. Occurrence of newly discovered human polyomaviruses in skin of liver transplant recipients and their relation with squamous cell carcinoma in situ and actinic keratosis - a single-center cohort study. *Transplant Int* 2019; 32 (5): 516.
19. Goh S, Lindau C, Tiveljung-Lindell A, Allander T. Merkel cell polyomavirus in respiratory tract secretions. *Emerg Infect Dis* 2009; 15 (3): 489.

20. van der Meijden E, Wunderink HF, van der Blij-de Brouwer CS, et al. Human polyomavirus 9 infection in kidney transplant patients. *Emerg Infect Dis* 2014; 20 (6): 991.
21. Bialasiewicz S, Rockett RJ, Barraclough KA, et al. Detection of Recently Discovered Human Polyomaviruses in a Longitudinal Kidney Transplant Cohort. *Am J Transplant* 2016; 16 (9): 2734.
22. van Rijn AL, Wunderink HF, de Brouwer CS, van der Meijden E, Rotmans JJ, Feltkamp MCW. Impact of HPyV9 and TSPyV coinfection on the development of BK polyomavirus viremia and associated nephropathy after kidney transplantation. *J Med Virol* 2019; 91 (6): 1142.
23. Signorini L, Belingheri M, Ambrogi F, et al. High frequency of Merkel cell polyomavirus DNA in the urine of kidney transplant recipients and healthy controls. *J Clin Virol* 2014; 61 (4): 565.
24. Hussein MI, Anastasi B, Singer J, Lacey SF. A comparative study of Merkel cell, BK and JC polyomavirus infections in renal transplant recipients and healthy subjects. *J Clin Virol* 2010; 49 (2): 137.
25. Fajfr M, Pliskova L, Kutova R, et al. Human polyomavirus 9 in immunocompromised patients in the University Hospital in Hradec Kralove, Czech Republic. *J Med Virol* 2017; 89 (12): 2230.
26. van der Meijden E, Wunderink HF, van der Blij-de Brouwer CS, et al. Human polyomavirus 9 infection in kidney transplant patients. *Emerg Infect Dis* 2014; 20 (6): 991.

Figure Legends

Figure 1

HPyV DNA in blood and urine in KTRs over time. The insert shows the logarithm of the MCPyV DNA copy number per mL (y) plotted against the post transplantation time (x). A: HPyV in blood. The square box indicates BKPyV DNA, upwards triangle shows JCPyV DNA, ringed cross indicates MCPyV DNA, and downwards triangle is HPyV9 DNA. In one patient TSPyV was detected by multiplex analysis, the DNA load, however, was too low to be quantified by qPCR and is therefore not shown. B: HPyV in urine. The square box indicates BKPyV DNA, upwards triangle shows JCPyV DNA, and ringed cross indicates MCPyV DNA.

Figure 2

Patients with episodes of MCPyV DNA detection during the follow-up post-transplantation. The logarithm of the MCPyV DNA copy number per mL is shown on the Y-axis, and day after the transplantation shown on the x-axis. Dashed lines separate individual patients. White and black bars indicate positive MCPyV findings in urine and in blood, respectively. Hash indicates a positive MCPyV DNA detection episode which coincided with BKPyV DNAemia. Stars indicate MCPyV DNA detection episodes which coincided with histological verification of PVAN.

Table 1. Comparison of BKPyV/JCPyV qPCR and multiplex PCR

BKPyV in EDTA-plasma**Kappa=0.88**

		qPCR		
Multiplex PCR		+	-	Total
	+	237	0	237
	-	23	140	163
	Total	260	140	400

BKPyV in Urine**Kappa=0.91**

		qPCR		
Multiplex PCR		+	-	Total
	+	302	8	310
	-	3	75	78
	Total	305	83	388

JCPyV in EDTA-plasma**Kappa=0.77**

		qPCR		
Multiplex PCR		+	-	Total
	+	45	0	44
	-	23	333	356
	Total	67	333	400

JCPyV in Urine**Kappa=0.76**

		qPCR		
Multiplex PCR		+	-	Total
	+	125	0	125
	-	45	218	263
	Total	170	218	388

Table 2: Non BKPyV/JCPyV HPyV detection in relation to clinical severity of most severe BKPyV DNAemia episode during follow-up

Journal Pre-proof

		no BKPyV and JCPyV DNAemia	BKPyV DNA load in blood			Difference among the groups
			<10 ⁴ copies/ml	>10 ⁴ copies/ml	>10 ⁴ copies/ml + histologically verified PVAN	
number of patients		14	19	45	19	
peak BKPyV DNAemia	DNA load (median, range; copies/ml)	-	1.60x10 ³ , 1.00x10 ² -5.50x10 ³	3.90x10 ⁴ , 1.00x10 ² -1.00x10 ⁷	7.80x10 ⁵ , 1.10x10 ⁴ - 1.50x10 ⁹	<i>p</i> <0.0001*
decoy cells	% (median, range)	-	1, 0-80	70, 0-95	90, 60-99	<i>p</i> <0.0001*
decrease of renal function ++	number of patients, %	-	1/19, 5%	14/45, 31%	17/19, 89%	<i>p</i> <0.0001**
additional JCPyV DNAemia	number of patients, %	-	1/19, 5%	19/45, 42%	7/19, 37%	<i>p</i> =0.001**
	DNA load (median. range; copies/ml)	-	1.00x10 ²	1.80x10 ³ , 1.00x10 ² -8.00x10 ⁵	3.60x10 ⁴ , 5.00x10 ² -5.00x10 ⁵	<i>p</i> =0.018***
detection of non BKPyV/JCPyV HPyVs (in number of patients)						

during BKPyV/JCPyV DNAemia	in urine	-	none	3 (MCPyV)	6 (all MCPyV)	$p=0.005^{**}$
	in blood	-	1 (MCPyV)	3 (2xMCPyV, 1xHPyV9)	3 (all MCPyV)	$p=0.560^{**}$
in absence of BKPyV/JCPyV DNAemia	in urine	1 (MCPyV)	3 (all MCPyV)	3 (all MCPyV)	none	$p=0.291^{**}$
	in blood	none	1 (TSPyV)	2 (all MCPyV)	none	$p=0.999^{**}$

Abbreviations: BKPyV: BK Polyomavirus, JCPyV: JC polyomavirus, HPyV: Human Polyomavirus, eGFR: estimated glomerular filtration rate. PVAN: Polyomavirus associated nephropathy
+ with respect to: (1) highest BKPyV DNA load in blood, (2) highest decoy cell level, (3) eventual decrease of eGFR and (4) eventual verification of PVAN by histology

++ $\geq 15\%$ decrease of eGFR. as compared to mean of the 3 preceding measurements

* non-parametric Kruskal-Wallis t-test

** Fisher's exact test

*** Mann-Whitney t-test